Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

Amlodipine/Valsartan [Design Issues]

posted by Bebac user – Egypt, 2023-09-09 08:34 (670 d 11:49 ago) – Posting: # 23713
Views: 4,880

The combination of Amlodipine and valsartan was published as two periods crossover but after checking the variability of Valsartan, it had more than 30%. Therefore, should I in those cases design this study as replicated or un-replicated ?

Complete thread:

Amlodipine/ValsartanBebac user 2023-09-09 06:34 [Design Issues]
- Amlodipine/Valsartan Helmut 2023-09-12 06:48
  - Amlodipine/Valsartan Kumarnaidu2 2023-12-06 09:36
    - Amlodipine/Valsartan dshah 2023-12-06 16:49
      - Amlodipine/Valsartan Kumarnaidu2 2023-12-07 02:42
    - Use all data and avoid the partial replicate design for the FDA Helmut 2023-12-07 09:01

Admin contact
23,430 posts in 4,931 threads, 1,679 registered users;
66 visitors (1 registered, 65 guests [including 7 identified bots]).
Forum time: 20:23 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge. Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz